{"id":"NCT03376516","sponsor":"Octapharma","briefTitle":"Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A","officialTitle":"Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-22","primaryCompletion":"2018-11-03","completion":"2018-11-03","firstPosted":"2017-12-18","resultsPosted":"2019-12-24","lastUpdate":"2021-01-19"},"enrollment":11,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Severe Hemophilia A"],"interventions":[{"type":"DRUG","name":"Wilate","otherNames":[]}],"arms":[{"label":"All patients","type":"EXPERIMENTAL"}],"summary":"A prospective, non-controlled, international, multi-centre phase 3 study to investigate the pharmacokinetics, efficacy, safety, and immunogenicity of Wilate in previously treated children with severe haemophilia A","primaryOutcome":{"measure":"Pharmacokinetic (PK) Assessment (Area Under the Curve (AUC)) of FVIII:C","timeFrame":"0h, 0.25h, 1h, 6h, 24h and 48 h following a single dose of Wilate","effectByArm":[{"arm":"Wilate","deltaMin":768.8,"sd":288.5}],"pValues":[]},"eligibility":{"minAge":"1 Year","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":3,"countries":["Russia","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":10},"commonTop":["Respiratory tract infection","Varicella","Viral upper respiratory tract infection","Headache","Parvovirus B19 test positive"]}}